Synta Pharmaceuticals Announces Proposed Registered Direct Offering of Common Stock

  Synta Pharmaceuticals Announces Proposed Registered Direct Offering of
  Common Stock

Business Wire

LEXINGTON, Mass. -- December 12, 2012

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that it has
commenced an issuer directed, registered direct offering of its common stock.
Shares will be priced at today's closing market value, and Synta expects to
raise gross proceeds of approximately $40 million to $50 million. No
underwriter or placement agent will be used in this transaction. Members of
Synta’s Board of Directors are expected to participate in the offering.

Net proceeds from the offering will be used to fund Synta's operations,
including, research and development, clinical trials, manufacturing,
intellectual property protection and enforcement, and working capital, and for
other general corporate purposes.

The securities described above are being offered by Synta Pharmaceuticals
pursuant to a registration statement previously filed and declared effective
by the Securities and Exchange Commission. The securities may be offered only
by means of a prospectus, including a prospectus supplement, forming a part of
the effective registration statement. When available, copies of the final
prospectus supplement and accompanying base prospectus relating to this
offering may be obtained directly from the Company at 45 Hartwell Avenue,
Lexington, Massachusetts 02421, Attn: Investor Relations (781-274-8200) or
from the website of the Securities and Exchange Commission at

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities of Synta Pharmaceuticals Corp. nor shall
there be any sale of securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including
cancer and chronic inflammatory diseases. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities.

Safe Harbor Statement

This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp., including, but not limited to, whether an offering will
actually be consummated, the expected size of the offering and the expected
use of the proceeds from the offering. Such forward-looking statements can be
identified by the use of forward-looking terminology such as “will”, “would”,
“should”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “may”,
“estimates”, “predicts”, “projects”, or similar expressions intended to
identify forward-looking statements. Such statements, reflect our current
views with respect to future events and are based on assumptions and subject
to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements,
including those described in “Risk Factors” of our Form 10-K for the year
ended December 31, 2011 as filed with the Securities and Exchange Commission.
Synta undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.


Investor Relations Contact:
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
Press spacebar to pause and continue. Press esc to stop.